Head to Head Review: Scienture (NASDAQ:SCNX) & Aldeyra Therapeutics (NASDAQ:ALDX)

Scienture (NASDAQ:SCNX) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Risk and Volatility

Scienture has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Profitability

This table compares Scienture and Aldeyra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-25.18%	-19.22%
Aldeyra Therapeutics	N/A	-72.25%	-47.92%

Institutional and Insider Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 21.4% of Scienture shares are owned by insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Scienture and Aldeyra Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	0	0	1.00
Aldeyra Therapeutics	1	1	2	0	2.25

Aldeyra Therapeutics has a consensus target price of $9.50, indicating a potential upside of 124.06%. Given Aldeyra Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Scienture.

Earnings & Valuation

This table compares Scienture and Aldeyra Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$653,391.00	32.03	$9.07 million	($1.00)	-0.52
Aldeyra Therapeutics	N/A	N/A	-$55.85 million	($0.73)	-5.81

Scienture has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Summary

Scienture beats Aldeyra Therapeutics on 7 of the 12 factors compared between the two stocks.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.